Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed acro
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed acro